{"id":43579,"date":"2025-10-16T16:12:00","date_gmt":"2025-10-16T08:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=43579"},"modified":"2025-10-16T16:12:00","modified_gmt":"2025-10-16T08:12:00","slug":"abbott-reports-q3-2025-revenue-of-11-369-b-up-6-9-yoy-strong-growth-across-nutrition-devices-segments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43579","title":{"rendered":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments"},"content":{"rendered":"\n<p>Abbott Laboratories (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABT:NYSE\">NYSE: ABT<\/a>) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of <strong>$32.869\u202fB<\/strong>, a year\u2011over\u2011year (YoY) increase of <strong>6.1\u202f%<\/strong>. In the third quarter alone, revenue reached <strong>$11.369\u202fB<\/strong>, up <strong>6.9\u202f% YoY<\/strong>. Operating margin stood at <strong>18.1\u202f% of sales<\/strong>, while the adjusted operating margin rose <strong>23.0\u202f%<\/strong>, reflecting a <strong>40\u2011basis\u2011point<\/strong> lift.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-segment-performance-q3-2025\">Segment Performance \u2013 Q3 2025<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Revenue<\/th><th>YoY Change<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Nutrition<\/strong><\/td><td>$2.153\u202fB<\/td><td>+4.2\u202f%<\/td><td>Growth of <strong>Ensure\u00ae<\/strong> and <strong>Glucerna<\/strong> brands<\/td><\/tr><tr><td><strong>Diagnostics<\/strong><\/td><td>$2.253\u202fB<\/td><td>\u20136.6\u202f% (incl. COVID\u201119)<\/td><td>0.4\u202f% organic growth; China procurement headwinds<\/td><\/tr><tr><td><strong>Established Pharmaceuticals<\/strong><\/td><td>$1.511\u202fB<\/td><td>+7.5\u202f%<\/td><td>10.3\u202f% reported, 11.1\u202f% organic growth in Emerging Markets<\/td><\/tr><tr><td><strong>Medical Devices<\/strong><\/td><td>$5.448\u202fB<\/td><td>+14.8\u202f%<\/td><td>Double\u2011digit gains in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, Structural Heart<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-diabetes-care-highlights\">Diabetes Care Highlights<\/h4>\n\n\n\n<p>Continuous glucose monitors (CGMs) sales totaled <strong>$2.0\u202fB<\/strong>, a <strong>20.5\u202f%<\/strong> increase YoY.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-guidance-amp-outlook\">Guidance &amp; Outlook<\/h3>\n\n\n\n<p>Abbott reaffirms its full\u2011year 2025 organic sales growth guidance of <strong>7.5\u202f% to 8.0\u202f%<\/strong> (excluding COVID\u201119 testing sales) or <strong>6.0\u202f% to 7.0\u202f%<\/strong> (including COVID\u201119 sales). The company remains confident that its diversified portfolio and strong pipeline will sustain growth momentum into 2026.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-investor-takeaways\">Investor Takeaways<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue growth<\/strong> driven by <strong>Nutrition<\/strong> and <strong>Medical Devices<\/strong> segments.<\/li>\n\n\n\n<li><strong>Operating margin<\/strong> improvement reflects cost discipline and high\u2011margin product mix.<\/li>\n\n\n\n<li><strong>Diagnostics<\/strong> growth is muted, primarily due to external market forces rather than product performance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/ABT-2025-Q3-Earnings-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ABT-2025 Q3-Earnings Release.\"><\/object><a id=\"wp-block-file--media-6591cd56-6c25-4bed-9053-bf5292df4695\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/ABT-2025-Q3-Earnings-Release.pdf\">ABT-2025 Q3-Earnings Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/ABT-2025-Q3-Earnings-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6591cd56-6c25-4bed-9053-bf5292df4695\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43581,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[503,27,870],"class_list":["post-43579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-abbott","tag-finanical-reports","tag-nyse-abt"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of $32.869\u202fB, a year\u2011over\u2011year (YoY) increase of 6.1\u202f%. In the third quarter alone, revenue reached $11.369\u202fB, up 6.9\u202f% YoY. Operating margin stood at 18.1\u202f% of sales, while the adjusted operating margin rose 23.0\u202f%, reflecting a 40\u2011basis\u2011point lift.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43579\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments\" \/>\n<meta property=\"og:description\" content=\"Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of $32.869\u202fB, a year\u2011over\u2011year (YoY) increase of 6.1\u202f%. In the third quarter alone, revenue reached $11.369\u202fB, up 6.9\u202f% YoY. Operating margin stood at 18.1\u202f% of sales, while the adjusted operating margin rose 23.0\u202f%, reflecting a 40\u2011basis\u2011point lift.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43579\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-16T08:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments\",\"datePublished\":\"2025-10-16T08:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1603.webp\",\"keywords\":[\"Abbott\",\"Finanical Reports\",\"NYSE: ABT\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43579#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43579\",\"name\":\"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1603.webp\",\"datePublished\":\"2025-10-16T08:12:00+00:00\",\"description\":\"Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of $32.869\u202fB, a year\u2011over\u2011year (YoY) increase of 6.1\u202f%. In the third quarter alone, revenue reached $11.369\u202fB, up 6.9\u202f% YoY. Operating margin stood at 18.1\u202f% of sales, while the adjusted operating margin rose 23.0\u202f%, reflecting a 40\u2011basis\u2011point lift.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43579\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition & Devices Segments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43579#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments - Insight, China&#039;s Pharmaceutical Industry","description":"Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of $32.869\u202fB, a year\u2011over\u2011year (YoY) increase of 6.1\u202f%. In the third quarter alone, revenue reached $11.369\u202fB, up 6.9\u202f% YoY. Operating margin stood at 18.1\u202f% of sales, while the adjusted operating margin rose 23.0\u202f%, reflecting a 40\u2011basis\u2011point lift.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43579","og_locale":"en_US","og_type":"article","og_title":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments","og_description":"Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of $32.869\u202fB, a year\u2011over\u2011year (YoY) increase of 6.1\u202f%. In the third quarter alone, revenue reached $11.369\u202fB, up 6.9\u202f% YoY. Operating margin stood at 18.1\u202f% of sales, while the adjusted operating margin rose 23.0\u202f%, reflecting a 40\u2011basis\u2011point lift.","og_url":"https:\/\/flcube.com\/?p=43579","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-16T08:12:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43579#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43579"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments","datePublished":"2025-10-16T08:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43579"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43579#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp","keywords":["Abbott","Finanical Reports","NYSE: ABT"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43579#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43579","url":"https:\/\/flcube.com\/?p=43579","name":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43579#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43579#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp","datePublished":"2025-10-16T08:12:00+00:00","description":"Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September\u202f30,\u202f2025. For the first nine months of 2025 the company posted revenue of $32.869\u202fB, a year\u2011over\u2011year (YoY) increase of 6.1\u202f%. In the third quarter alone, revenue reached $11.369\u202fB, up 6.9\u202f% YoY. Operating margin stood at 18.1\u202f% of sales, while the adjusted operating margin rose 23.0\u202f%, reflecting a 40\u2011basis\u2011point lift.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43579#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43579"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43579#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp","width":1080,"height":608,"caption":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition & Devices Segments"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43579#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbott Reports Q3 2025 Revenue of $11.369\u202fB, Up 6.9% YoY \u2013 Strong Growth Across Nutrition &amp; Devices Segments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43579"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43579\/revisions"}],"predecessor-version":[{"id":43582,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43579\/revisions\/43582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43581"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}